Zymeworks Price to Free Cash Flow Ratio 2016-2022 | ZYME

Historical price to free cash flow ratio values for Zymeworks (ZYME) since 2016. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Zymeworks Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-01-26 9.75 0.00
2022-06-30 5.30 $-3.87 0.00
2022-03-31 6.55 $-4.09 0.00
2021-12-31 16.39 $-3.93 0.00
2021-09-30 29.04 $-3.86 0.00
2021-06-30 34.69 $-3.15 0.00
2021-03-31 31.58 $-3.12 0.00
2020-12-31 47.26 $-3.09 0.00
2020-09-30 46.58 $-3.27 0.00
2020-06-30 36.07 $-2.99 0.00
2020-03-31 35.47 $-2.43 0.00
2019-12-31 45.46 $-2.32 0.00
2019-09-30 24.80 $0.49 50.79
2019-06-30 22.00 $0.21 104.17
2019-03-31 16.18 $0.83 19.45
2018-12-31 14.68 $0.80 18.27
2018-09-30 15.70 $0.42 37.28
2018-06-30 14.78 $1.01 14.69
2018-03-31 12.02 $-0.78 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.616B $0.027B
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.571B 9.49
GSK (GSK) United Kingdom $71.996B 8.97
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.433B 19.52
Ginkgo Bioworks Holdings (DNA) United States $3.414B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.676B 25.16
Biohaven (BHVN) United States $1.305B 0.00
Emergent Biosolutions (EBS) United States $0.671B 5.28
ADC Therapeutics SA (ADCT) Switzerland $0.359B 0.00
Ambrx Biopharma (AMAM) United States $0.083B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.028B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00